Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CLIFTON FULLER and WILLIAM H MORRISON.
CLIFTON FULLER
Connection Strength
4.803
WILLIAM H MORRISON
  1. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Curr Oncol. 2022 08 31; 29(9):6303-6313.
    View in: PubMed
    Score: 0.214
  2. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol. 2022 Jan; 32:35-40.
    View in: PubMed
    Score: 0.202
  3. Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer. 2020 02 15; 126(4):749-756.
    View in: PubMed
    Score: 0.176
  4. Author Correction: Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018 11 27; 5(1):1.
    View in: PubMed
    Score: 0.165
  5. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903.
    View in: PubMed
    Score: 0.163
  6. Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018 09 04; 5:180173.
    View in: PubMed
    Score: 0.162
  7. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 09; 40(9):2060-2069.
    View in: PubMed
    Score: 0.159
  8. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
    View in: PubMed
    Score: 0.148
  9. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016 12; 38(12):1739-1751.
    View in: PubMed
    Score: 0.140
  10. Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E452-8.
    View in: PubMed
    Score: 0.130
  11. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15; 121(10):1608-19.
    View in: PubMed
    Score: 0.126
  12. Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiother Oncol. 2014 Sep; 112(3):321-5.
    View in: PubMed
    Score: 0.123
  13. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol. 2014 May; 111(2):281-8.
    View in: PubMed
    Score: 0.120
  14. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Phys Imaging Radiat Oncol. 2024 Jan; 29:100540.
    View in: PubMed
    Score: 0.059
  15. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol. 2023 11; 188:109892.
    View in: PubMed
    Score: 0.057
  16. Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio. Cancers (Basel). 2023 Aug 29; 15(17).
    View in: PubMed
    Score: 0.057
  17. Temporal characterization of acute pain and toxicity kinetics during radiation therapy for head and neck cancer. A retrospective study. Oral Oncol Rep. 2023 Sep; 7.
    View in: PubMed
    Score: 0.057
  18. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. AMIA Annu Symp Proc. 2021; 2021:979-988.
    View in: PubMed
    Score: 0.052
  19. Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clin Transl Radiat Oncol. 2021 Sep; 30:78-83.
    View in: PubMed
    Score: 0.050
  20. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021 11; 43(11):3331-3344.
    View in: PubMed
    Score: 0.049
  21. Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther. 2021; 8(1):213-222.
    View in: PubMed
    Score: 0.049
  22. Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. Int J Part Ther. 2021; 8(1):319-327.
    View in: PubMed
    Score: 0.049
  23. Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2021 06; 159:21-27.
    View in: PubMed
    Score: 0.048
  24. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
    View in: PubMed
    Score: 0.047
  25. Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. J Appl Clin Med Phys. 2021 Jan; 22(1):37-44.
    View in: PubMed
    Score: 0.047
  26. Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer. 2020 Sep 23; 20(1):912.
    View in: PubMed
    Score: 0.047
  27. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
    View in: PubMed
    Score: 0.046
  28. Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma. Head Neck. 2020 10; 42(10):2791-2800.
    View in: PubMed
    Score: 0.046
  29. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):929-935.
    View in: PubMed
    Score: 0.046
  30. A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncol. 2020 07; 106:104665.
    View in: PubMed
    Score: 0.045
  31. SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):363-371.
    View in: PubMed
    Score: 0.045
  32. Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck. 2020 08; 42(8):2137-2144.
    View in: PubMed
    Score: 0.045
  33. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020 08; 42(8):1939-1953.
    View in: PubMed
    Score: 0.045
  34. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
    View in: PubMed
    Score: 0.044
  35. Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):185-193.
    View in: PubMed
    Score: 0.044
  36. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22.
    View in: PubMed
    Score: 0.044
  37. Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiat Oncol. 2019 Aug 19; 14(1):148.
    View in: PubMed
    Score: 0.043
  38. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
    View in: PubMed
    Score: 0.043
  39. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
    View in: PubMed
    Score: 0.043
  40. Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
    View in: PubMed
    Score: 0.043
  41. Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Phys Imaging Radiat Oncol. 2019 Apr; 10:29-34.
    View in: PubMed
    Score: 0.042
  42. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
    View in: PubMed
    Score: 0.042
  43. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
    View in: PubMed
    Score: 0.042
  44. Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope. 2020 01; 130(1):146-153.
    View in: PubMed
    Score: 0.042
  45. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019 05 01; 125(9):1536-1546.
    View in: PubMed
    Score: 0.042
  46. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. Oral Oncol. 2019 01; 88:66-74.
    View in: PubMed
    Score: 0.041
  47. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.
    View in: PubMed
    Score: 0.040
  48. Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. J Neurosurg. 2019 03 01; 130(3):812-821.
    View in: PubMed
    Score: 0.040
  49. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8.
    View in: PubMed
    Score: 0.039
  50. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
    View in: PubMed
    Score: 0.039
  51. Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiother Oncol. 2018 01; 126(1):75-80.
    View in: PubMed
    Score: 0.039
  52. Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
    View in: PubMed
    Score: 0.038
  53. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
    View in: PubMed
    Score: 0.038
  54. Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiat Oncol. 2017 Aug 15; 12(1):129.
    View in: PubMed
    Score: 0.038
  55. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056.
    View in: PubMed
    Score: 0.038
  56. Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017 10; 39(10):2079-2087.
    View in: PubMed
    Score: 0.038
  57. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol. 2017 09; 72:90-97.
    View in: PubMed
    Score: 0.037
  58. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck?Cancer. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1002-1011.
    View in: PubMed
    Score: 0.037
  59. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017 05 01; 123(9):1653-1661.
    View in: PubMed
    Score: 0.036
  60. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
    View in: PubMed
    Score: 0.036
  61. Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 07 01; 98(3):532-540.
    View in: PubMed
    Score: 0.036
  62. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 2016 11 15; 122(21):3411-3412.
    View in: PubMed
    Score: 0.035
  63. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016 Jun 01; 2(6):782-9.
    View in: PubMed
    Score: 0.035
  64. Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):30-41.
    View in: PubMed
    Score: 0.034
  65. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
    View in: PubMed
    Score: 0.034
  66. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1117-31.
    View in: PubMed
    Score: 0.034
  67. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head Neck. 2016 04; 38 Suppl 1:E2091-9.
    View in: PubMed
    Score: 0.034
  68. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.034
  69. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
    View in: PubMed
    Score: 0.033
  70. Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head Neck. 2016 04; 38 Suppl 1:E1459-66.
    View in: PubMed
    Score: 0.033
  71. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):241-247.
    View in: PubMed
    Score: 0.033
  72. Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiother Oncol. 2015 Oct; 117(1):132-8.
    View in: PubMed
    Score: 0.033
  73. A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):344-352.
    View in: PubMed
    Score: 0.033
  74. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E925-33.
    View in: PubMed
    Score: 0.033
  75. Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. Head Neck. 2016 04; 38 Suppl 1:E580-7.
    View in: PubMed
    Score: 0.033
  76. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral Oncol. 2015 Feb; 51(2):195-201.
    View in: PubMed
    Score: 0.031
  77. Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg. 2014 Oct; 151(4):619-26.
    View in: PubMed
    Score: 0.031
  78. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014 Oct 01; 120(19):3082-8.
    View in: PubMed
    Score: 0.030
  79. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014 Jul 01; 120(13):1975-84.
    View in: PubMed
    Score: 0.030
  80. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013 Sep 01; 119(17):3162-9.
    View in: PubMed
    Score: 0.028
  81. Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):455-61.
    View in: PubMed
    Score: 0.022
  82. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):747-55.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.